<DOC>
	<DOCNO>NCT01261572</DOCNO>
	<brief_summary>To find effective dos ASP3550 maintenance serum testosterone suppression patient prostate cancer .</brief_summary>
	<brief_title>Study Find Maintenance Dose Periodic Administration ASP3550</brief_title>
	<detailed_description>ASP3550 administer periodically patient prostate cancer . The primary efficacy variable effect ASP3550 maintenance serum testosterone suppression . In addition , safety pharmacokinetics ASP3550 investigate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven prostate cancer ( adenocarcinoma ) stag A patient endocrine treatment indicate . Patients rise serum PSA prostatectomy radiotherapy perform curative intention Serum testosterone level 2.2 ng/mL An ECOG ( Eastern Cooperative Oncology Group ) P.S . ( Performance Status ) score 0 2 Serum PSA level 2 ng/mL Previous present endocrine treatment prostate cancer . However , patient undergo neoadjuvant/adjuvant endocrine therapy maximal duration 6 month prostatectomy radiotherapy terminate least 6 month Treated 5Î±reductase inhibitor A candidate curative therapy , i.e. , radical prostatectomy radiotherapy within 12 month Concurrent history severe liver disease Abnormal ECG long QTc A patient receive ASP3550 past time Administered drug another clinical study postmarket clinical study 28 day prior study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ASP3550</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostatic neoplasm</keyword>
</DOC>